康泰生物：三价流感病毒裂解疫苗（MDCK细胞）获得药物临床试验批准通知书

Core Viewpoint - Kangtai Biological (300601.SZ) has received approval from the National Medical Products Administration for its trivalent influenza virus split vaccine (MDCK cell) for clinical trials, marking a significant step in its vaccine development efforts [1] Company Summary - The trivalent influenza virus split vaccine is designed for individuals aged 3 years and older, aiming to stimulate the immune system to produce antibodies against influenza viruses [1] - This vaccine is intended for the prevention of influenza caused by vaccine-related strains of the virus [1] - Currently, there are no approved trivalent influenza virus split vaccines (MDCK cell) available in the domestic market [1] Industry Summary - The approval of this vaccine follows the precedent set by international manufacturers such as Seqirus, which have successfully launched MDCK cell-based influenza vaccines [1] - The development of this vaccine could enhance the competitive landscape of influenza prevention in the domestic market [1]